ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Linagliptin

Also written as “BI 1356”, “linagliptin” and “Linagliptin/Metformin FDC”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Esophageal Neoplasms · Carcinoma, Non-Small-Cell Lung · Hypertension, led by 7 companies.

Drug pageLinagliptin: every studyMany companies study it; this page follows only the 89 they lead. All 129 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 21, 201189 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim800 open or runningphase 4since Sep 21, 2011Mar 31, 2006none ahead
Dong Wha Pharmaceuticalits history only30 open or runningphase 1since Aug 6, 2014Aug 6, 2014none ahead
Profil Institut für Stoffwechselforschungits history only20 open or runningphase 4since Jul 11, 2013Jul 11, 2013none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Aug 3, 2016Aug 3, 2016none ahead
ikfe-CROits history only10 open or runningphase 3since Feb 11, 2015Feb 11, 2015none ahead
Marcus Borchertits history only10 open or runningphase 4since Feb 21, 2012Feb 21, 2012none ahead
Nabiqasim Industries (Pvt)its history only11 open or runningphase 4since Feb 19, 2025Feb 19, 2025none ahead

Also a collaborator on its studies: Halozyme Therapeutics, BioLineRx, Eli Lilly, Eva Pharma, Ikfe and MLM Medical Labs.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Aug 25, 2010.

  1. Mar 7, 20142 phase 1 studies in HealthyNCT02084082, NCT02084056
  2. Apr 22, 2014Phase 1 study in HealthyNCT02121509 · 74 enrolled · Germany
  3. Jun 24, 20144 phase 1 studies in HealthyNCT02173665, NCT02173652, NCT02173639 and 1 more
  4. Jul 1, 201421 phase 1 studiesNCT02180503, NCT02183532, NCT02183506 and 18 more
  5. Jul 4, 2014Phase 2 study in Diabetes Mellitus, Type 2NCT02183324 · 72 enrolled
  6. Aug 19, 20143 phase 1 studies in HealthyNCT02221414, NCT02221401, NCT02220647
  7. Sep 15, 2014Phase 4 study in Diabetes Mellitus, Type 2NCT02240680 · 302 enrolled · United States, Australia, Belgium and more
  8. May 21, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02453555 · 275 enrolled · Japan
  9. Apr 29, 2016Phase 1 study in HealthyNCT02758171 · 56 enrolled · Germany
  10. Jun 24, 20162 phase 1 studies in HealthyNCT02815644, NCT02821910
  11. Aug 30, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02897349 · 206 enrolled · China
  12. Aug 22, 2017Phase 1 study in HealthyNCT03259490 · 30 enrolled · Germany
  13. Feb 6, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03429543 · 175 enrolled · United States, Argentina, Brazil and more
  14. Aug 9, 2018Phase 1 study in HealthyNCT03629054 · 30 enrolled · Germany

TargetBeta

DPP4 →read by rule
“A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
sitagliptinruleMerckphase 4123
gemigliptinruleLG Chemphase 430
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

The newest 60 of 80 Boehringer Ingelheim leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT03629054Healthy · Germany1CompletedNov 5, 201830
NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedOct 19, 2022175
NCT03259490Healthy · Germany1CompletedNov 13, 201730
NCT02897349Diabetes Mellitus, Type 2 · China3CompletedJan 11, 2019206
NCT02821910Healthy · Germany1CompletedOct 1, 201650
NCT02815644Healthy · Japan1CompletedOct 5, 201622
NCT02758171Healthy · Germany1CompletedJul 29, 201656
NCT02453555Diabetes Mellitus, Type 2 · Japan3CompletedAug 26, 2016275
NCT02240680Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more4CompletedApr 18, 2017302
NCT02221414Healthy1CompletedMar 201095
NCT02221401Healthy1CompletedApr 201096
NCT02220647Healthy1CompletedApr 201096
NCT02191228Renal Insufficiency1CompletedFeb 201051
NCT02183636Healthy1CompletedDec 200939
NCT02183623Healthy1CompletedOct 200520
NCT02183610Healthy1CompletedSep 200612
NCT02183584Healthy1CompletedOct 200916
NCT02183532Healthy1CompletedJul 200912
NCT02183506Healthy1CompletedDec 200516
NCT02183493Healthy1CompletedDec 200832
NCT02183480Healthy1CompletedSep 200912
NCT02183467Healthy1CompletedJun 200844
NCT02183428Healthy1CompletedJul 200820
NCT02183415Diabetes Mellitus, Type 21CompletedJan 200677
NCT02183402Healthy1CompletedSep 200820
NCT02183389Healthy1CompletedOct 200818
NCT02183376Hepatic Insufficiency1CompletedMar 200933
NCT02183363Healthy1CompletedMay 200724
NCT02183350Diabetes Mellitus, Type 21CompletedAug 200547
NCT02183337Healthy1CompletedApr 200720
NCT02183324Diabetes Mellitus, Type 22CompletedJun 200772
NCT02183311Healthy1CompletedOct 200656
NCT02183298Healthy1CompletedJul 200636
NCT02180503Healthy1CompletedOct 200524
NCT02175394Healthy1CompletedOct 200818
NCT02173665Healthy1CompletedDec 200464
NCT02173652Healthy1CompletedApr 200816
NCT02173639Healthy1CompletedJun 200920
NCT02121509Healthy · Germany1CompletedJul 201474
NCT02084082Healthy · Germany1CompletedJul 201468
NCT02084056Healthy · Germany1CompletedJul 201474
NCT01947153Healthy · Russian Federation1CompletedJan 201436
NCT01897532Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more4CompletedJan 18, 20186,991
NCT01845077Healthy · United States1CompletedAug 201372
NCT01792518Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more3CompletedNov 2015360
NCT01708902Diabetes Mellitus, Type 2 · China, Malaysia, Philippines and more3CompletedApr 2014876
NCT01703286Diabetes Mellitus, Type 2 · Germany1CompletedJan 201442
NCT01581931Healthy · Germany1CompletedJun 201232
NCT01540487Healthy · China1CompletedJun 201248
NCT01512979Diabetes Mellitus, Type 2 · United States, Canada, India and more4CompletedApr 2013316
NCT01438814Diabetes Mellitus, Type 2 · Bangladesh, Belgium, Canada and more4CompletedMar 2013689
NCT01342484Diabetes Mellitus, Type 2 · United States, Canada, France and more2CompletedFeb 201640
NCT01276327Healthy · Germany1CompletedMay 201164
NCT01243424Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedAug 21, 20186,103
NCT01216397Healthy · Germany1CompletedDec 201040
NCT01215097Diabetes Mellitus, Type 2 · China, Malaysia, Philippines3CompletedApr 2012306
NCT01214239Diabetes Mellitus, Type 2 · China, Malaysia, Philippines3CompletedMay 2012300
NCT01204294Diabetes Mellitus, Type 2 · Japan3CompletedJan 2012574
NCT01194830Diabetes Mellitus, Type 2 · United States3CompletedOct 2011234
NCT01189201Healthy · Germany1CompletedNov 201042

How it is read

Names in the registry

  • “Linagliptin”, 35 entries
  • “BI 1356”, 14 entries
  • “linagliptin”, 10 entries
  • “Linagliptin/Metformin FDC”, 4 entries
  • “BI 1356 BS”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.